This page shows the latest TAK-003 news and features for those working in and with pharma, biotech and healthcare.
Takeda’s dengue vaccine, Qdenga (TAK-003), has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) for those aged four years and older, the company announced.
Nimbus recently announced positive top-line results from a phase 2b study evaluating NDI-034858, which will be known as TAK-279 upon completion of the transaction, for patients with ... Earlier this month, Takeda’s dengue vaccine candidate, Qdenga
Takeda’s dengue vaccine candidate, Qdenga (TAK-003), has been approved by the European Commission (EC) for the prevention of dengue disease in individuals aged four years and over, the company
Takeda’s dengue vaccine candidate, TAK-003, has been recommended for conditional marketing authorisation for the prevention of dengue disease caused by any serotype in individuals four years and older in ... the follow-up, TAK-003 prevented 84% of
Dengue vaccine TAK-003:Takeda’s dengue fever vaccine candidate TAK-003 hit the efficacy mark in a large-scale study reported earlier this month, and seems to be safe in ... In September, it presented proof-of-concept data suggesting one candidate –
Appears unaffected by serious safety issue affecting Sanofi rival. Takeda says new data shows its candidate vaccine for dengue fever TAK-003 is effective, and crucially doesn’t seem to be ... It’s also investing in production capacity for TAK-003,
More from news
Approximately 3 fully matching, plus 6 partially matching documents found.
Genetic Digital specialises in developing digital marketing solutions for the healthcare, medical and pharmaceutical sectors. From developing a digital strategy,...